The Rise of Polygenic Risk Scores: Can PGx Predict Susceptibility to Medication Side Effects?

Is the esoteric realm of genomics rendering conventional approaches to anticipating drug reactions and side effects archaic?
Pharmacogenomics (PGx) ushers in a novel epoch of pharmaceutical intervention, capitalizing on individual genetic signatures to tailor medical protocols. Through this approach, medication dosages are meticulously honed, curtailing the occurrence of adverse drug reactions (ADRs)1. Polygenic risk scores (PRS) stand at the vanguard of this paradigm shift, presenting a sophisticated framework to evaluate the multifaceted genetic underpinnings of maladies and the idiosyncratic reactions to drugs1. Departing from the rudimentary analysis of singular genetic mutations, PRS provides a holistic route to anticipate disease susceptibility and gauge treatment effectiveness on a personal level2. The upshot from myriad investigations is the inceptive recognition that ailments of a convoluted nature often root in genetics, urgin...